Other substances

Lamivudine

A nucleoside analogue.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Lamivudine is a synthetic nucleoside analogue. It acts through inhibition of viral DNA polymerisation. Lamivudine is used for treatment of hepatitis B virus and human immunodeficiency virus 1 infection (NCIt).

Lamivudine on DrugBank
Lamivudine on PubChem
Lamivudine on Wikipedia

Marketed as

3TC; AMILITRAP; ANTIHEB; AVILAM; AVOLAM; COMBIVIR; EPIVIR; FLAMIVUD; GANVIREL; HEPAVIR; HEPITEC; HEPTAVIR; HEPTODIN; HEPTODINE; HEPTOVIR; LAMDA; LAMIBERGEN; LAMIDAC; LAMITEC; LAMIVIR; LAMIVUDINE; ZEFFIX

C1C(OC(S1)CO)N2C=CC(=NC2=O)N

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model Preprint In silico	in silico			Feb/02/2020

AI-suggested references

Link	Publication date
Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment.	May/29/2020
Drug treatment options for the 2019-new coronavirus (2019-nCoV).	Dec/16/2021
Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?	Nov/30/2021
Structural insight into the binding interactions of NTPs and nucleotide analogues to RNA dependent RNA polymerase of SARS-CoV-2.	Jul/19/2021
Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections.	Dec/11/2021
Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19	Aug/05/2020
Putative Repurposing of Lamivudine, a Nucleoside/Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 Patients.	Jul/21/2021
Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs against Human Coronavirus 229E (HCoV-229E)	May/17/2020
An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).	Nov/23/2021
Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approach	Jul/07/2020

Export (.csv)